Acadia Pharmaceuticals
ACAD • NASDAQ
Acadia Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Catherine E. Owen Adams, with a market cap of $3.5B.
CEOCatherine E. Owen Adams
Next Earnings
Upcoming earnings announcement for Acadia Pharmaceuticals
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.07
Revenue Estimate
$283.8M
Earnings History
Past 12 earnings reports for Acadia Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | $0.14Est: $0.13 | +7.7% | $284.0MEst: $292.5M | -2.9% | — |
| Nov 5, 2025 | Q3 2025 | $0.26Est: $0.14 | +85.7% | $278.6MEst: $275.4M | +1.2% |  10-Q |
| Aug 6, 2025 | Q2 2025 | $0.16Est: $0.14 | +14.3% | $264.6MEst: $261.1M | +1.3% | 10-Q |
| May 7, 2025 | Q1 2025 | $0.11Est: -$0.03 | +466.7% | $244.3MEst: $239.3M | +2.1% | 10-Q |
| Feb 26, 2025 | Q4 2024 | $0.08Est: $0.23 | -65.2% | $259.6MEst: $277.7M | -6.5% | 10-K |
| Nov 6, 2024 | Q3 2024 | $0.20Est: $0.14 | +42.9% | $250.4MEst: $248.8M | +0.6% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.20Est: $0.19 | +5.3% | $242.0MEst: $236.0M | +2.5% | 10-Q |
| May 8, 2024 | Q1 2024 | $0.10Est: $0.05 | +100.0% | $205.8MEst: $208.4M | -1.2% | 10-Q |
| Feb 27, 2024 | Q4 2023 | $0.28Est: $0.30 | -6.7% | $231.0MEst: $223.7M | +3.3% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.40Est: -$0.43 | +7.0% | $211.7MEst: $189.5M | +11.7% | — |
| Aug 2, 2023 | Q2 2023 | $0.01Est: -$0.08 | +112.5% | $165.2MEst: $157.8M | +4.7% | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.27Est: -$0.21 | -28.6% | $118.5MEst: $120.3M | -1.5% | 10-Q |